Treosulfan-based Conditioning for Transplantation in AML/MDS
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The study hypotheses is that the introduction of dose escalated treosulfan, in substitution
to busulfan, will reduce toxicity after allogeneic transplantation while improving
myeloablation and and disease control in patients with AML and MDS not eligible for standard
transplantation.